Number of news items returned: 141 to 160 records of 375

Opmantek in record period of growth

26 April 2016


"The Opmantek management team was pleased to report excellent Q1 closing figures during a shareholder update web conference last Thursday. “The ...

IODM Market Update

26 April 2016


" Paradigm Metals Limited (“Paradigm” or “the Company”) is pleased to provide an IODM Market Summary as provided by the management of IODM. Focus ...

Integrity Compliance Systems' CEO invited to speak at major food safety conferences

22 April 2016


" ICS provide the only training course in Australia for Vulnerability Assessment and Critical Control Points (VACCP) plan, which is now ...

ATIC: New Revenue Streams

22 April 2016


"Funds Management services to start in June 2016 Until now ATIC’s core product has been equity research, and resulting buy/sell share ...

23rd Annual AustCham Westpac Australia-China Business Awards Winners Announced

14 April 2016


"Shanghai: 14th April - The AustCham Westpac Australia-China Business Awards Gala Dinner last night recognised Australian and Chinese businesses in ...

Integrity Compliance Solutions wins US based seafood processing giant Trident Seafood

06 April 2016


 Integrity Compliance Solutions wins US based seafood processing giant Trident Seafood    "It is an exciting time for Integrity Compliance Systems Limited ...

China Dairy IPO closes following solid demand

05 April 2016


"China Dairy Corporation Limited (“China Dairy or “the Company”) today announced the successful closure of its ASX IPO following solid ...

BlueMount Capital in Perth has expanded its senior ranks

05 April 2016


BlueMount Capital in Perth has expanded its senior ranks with the addition of Patrick Kedemos as Managing Partner and James ...

Everything you need to know about Building-integrated photovoltaics

30 March 2016


"...But while major installations might be few and far between, there are some exciting developments in design and innovation. Leading ...

Ocular Robotics: Ocular Technology Applied to Solve Structural Fatigue Testing Limitations, and March a Busy Time for Exhibition of Ocular Products Around the World

23 March 2016


"Ocular Technology Applied to Solve Structural Fatigue Testing Limitations One of the most exciting features of the OCR business for the ...

ATIC: Sales Team Growing & Marketing ramping up!

23 March 2016


"  4 full time sales staff, 2 more commencing 4th April 2016. Lead generation has commenced via online and telemarketing. 1 full time ...

Sales Team Growing & Marketing Ramping Up!

23 March 2016


" Australian Trading and Investment Corporation update SALES TEAM GROWING & MARKETING RAMPING UP! • 4 full time sales staff, 2 more commencing ...

appee to be used by Jean Hailes for Women's Health

18 March 2016


" Appee Ltd is please to announce more great news – The Jean Hailes for Women’s Health Foundation will be using ...

KOEL India and BioCubeā„¢ Corporation Ratify Manufacturing and Distribution agreement

14 March 2016


On March 9th 2016, the Board of Directors of Kirloskar Oil Engines Limited (KOEL) ratified a license agreement proposed between ...

Early Successes For Our Clients in 2016 - Funding Strategies Connect March 2016

11 March 2016


 Early Successes For Our Clients in 2016 - Funding Strategies Connect March 2016 Dear Readers, I have great progress to report for ...

Canada's Prime Minister Visits the BioCube

08 March 2016


 "Justin Trudeau, Prime Minister of Canada visits the BioCube™ The BioCube Corporation was delighted to have The Right Honourable Justin Trudeau, ...

BlueMount Capital: Finalist of the 23rd Annual Australia-China Business Awards

08 March 2016


  "23rd Annual Australia-China Business Awards Finalists Announced Shanghai: 8th March – The AustCham Westpac Australia-China Business Awards has received a record-breaking ...

Uchoose continues path of growth and operational expansion, establishes new and exciting line of business and welcomes leading industry authority to advisory role.

04 March 2016


"Uchoose again confirms its trajectory of growth with the favourable half yearly results being underpinned by some exciting developments in ...

Appee Ltd Announcement

04 March 2016


"Appee Ltd has drawn international attention by signing its first USA customer - Automobile Club of Southern California (a member ...

50% month-on-month revenue growth, expanding team and China

29 February 2016


"Squirel Ltd (“Squirel” or the “Company”) is pleased to announce the appointment of Fiona Hong a senior financial services professional ...

JNCI publication involving CytImmune's CYT-21625

10 March 18


"JNCI publication involving CytImmune's CYT-21625"


"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.

Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "


David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents